Claudio Tondo (Centro Cardiologico Monzio, Milan) discusses the benefits of hybrid ablation compared to the currently approved ablation methods in the treatment of atrial fibrillation. The hybrid ablation approach involves a combination of surgery with electrophysiological cathater ablation. It provides a beneficial for the treatment of patients with long-lasting and persistent atrial fibrillation. One advantage is the combining of expertise from both a surgeon and electrophysiologist within the same procedure. This gives the option to perform two ablations (endocardial and epicardial ablation) within the same surgery, which may increase the success rate in the long run. The abilty of the surgeon and electrophysiologist to review the outcome in real-time improves the efficacy and outcome of the procedure, as shown by robust data in the literature.
Patients with unsuccessful previous ablation procedures and patients with long-lasting persistent atrial fibrillation (over 1 year) are good candidates for the procedure.
Filmed at EHRA 2018, Barcelona.
View more content here.
1. What are the benefits of a hybrid ablation approach compared with other currently approved ablation methods? 0:07
2. Please describe the key efficacy and safety evidence supporting the use of hybrid ablation? 1:04
3. How do the atrial fibrillation recurrence rates compare with other approaches? 2:06
4. Are there certain patients who are more suitable for hybrid ablation? 3:05
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via open-access content in multimedia formats.
Share this Video
Related Videos In Interventional Cardiology
Zsolt Piroth, TCT 2022: The value of post-PCI FFR and intravascular imaging for cardiovascular failure, a FAME 3 substudy
This FAME 3 substudy aimed to define the value of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) and intravascular imaging for cardiovascular failure. In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the substudy of the FAME 3 trial and the implications for clinical practice. […]
Zsolt Piroth, TCT 2022: The value of measuring post-PCI FFR in patients with coronary artery disease
The impact of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) has been assessed in patients with coronary artery disease (CAD). In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the prognostic value for measuring post-PCI FFR and intravascular imaging in CAD. Click here for part […]
Ole De Backer, TCT 2022: FEops HEARTguide™ Computational Modelling for left atrial appendage (LAA) closure, the PREDICT LAA trial
The PREDICT LAA trial aimed to examine whether cardiac computed tomography- based FEops HEARTguide™ computational modelling would benefit clinical outcomes when planning for left atrial appendage (LAA) closure. In this touchCARDIO interview, we speak with Dr Ole De Backer (Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark) to discuss the PREDICT LAA trial and the next steps. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!